Andrea Lobo,  —

The 2024 National Patient Conference by the Myasthenia Gravis Foundation of America (MGFA) brought together more than 400 members of the myasthenia gravis (MG) community this week to educate participants about how to better manage their disease and raise awareness about treatments and clinical studies. “We are so…

People with myasthenia gravis (MG) — particularly those with more severe symptoms — are significantly hindered both in their ability to work and to engage in activities of daily living, a survey study reported. The impact of these impairments ranged from 13% to 40% across work time missed, as…

A young girl who showed unusual symptoms of ocular myasthenia gravis — persistent upper eyelid droopiness and outward deviation of the right eye — saw her symptoms ease after she received standard treatment, a case report shows. “This case emphasizes the diverse presentation of MG in ophthalmology, with ocular…

Timely rescue therapy use during a myasthenic crisis — a life-threatening complication of myasthenia gravis (MG) marked by severe breathing problems — can reduce mortality among patients. That’s according to new findings from researchers in China, who investigated risk factors associated with prolonged mechanical ventilation, which is commonly…

A 64-year-old woman with dropped head syndrome was found to have a form of myasthenia gravis (MG) associated with the presence of antibodies against a protein called muscle-specific kinase (MuSK) and axial myopathy, a condition where muscles that protect the spine become weak. Previous studies have reported axial myopathy…

Switching from maintenance therapeutic plasma exchange (TPE) to Vyvgart (efgartigimod) appeared to be well tolerated and effective for people with myasthenia gravis (MG), a short report suggests. “The good clinical response of this patient cohort, together with greater accessibility and convenience of infusion-based therapy, are notable advantages…

Cour Pharmaceuticals announced that it has raised $105 million in Series A financing to advance its investigational therapy, CNP-106, into a Phase 1b/2a clinical trial as a possible treatment of myasthenia gravis (MG). A company request for clinical testing of CNP-106 was cleared by the U.S.

Despite treatment, people with myasthenia gravis (MG) in the U.S. continue to experience exacerbations — episodes of disease worsening that may require urgent treatment and hospitalization — that carry high clinical and economic costs. That’s according to a large retrospective analysis of claims data for patients with employer-based commercial…

High levels of serum fibrinogen were found to be a sensitive and specific biomarker to identify people with myasthenia gravis (MG), according to a recent study. Fibrinogen is a plasma protein that participates in blood clotting and is usually not present in the serum. In MG patients, residual fibrinogen…

Health Canada has approved Vyvgart (efgartigimod alfa-fcab) to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR), the most common target of MG-causing antibodies. The approval is based on positive data from the Phase 3 ADAPT clinical trial (NCT03669588),…